

# Presbyopia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/P734F8047369EN.html>

Date: December 2022

Pages: 68

Price: US\$ 2,000.00 (Single User License)

ID: P734F8047369EN

## Abstracts

Presbyopia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Presbyopia - Drugs In Development, 2022, provides an overview of the Presbyopia (Ophthalmology) pipeline landscape.

Presbyopia is an eye condition in which eye slowly loses the ability to focus quickly on objects that are close. Presbyopia happens in people as they age. Signs and symptoms include headaches, eyestrain, difficulty reading small print and fatigue. Risk factors include anemia, diabetes, cardiovascular disease, hyperopia, multiple sclerosis, myasthenia gravis and eye trauma.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Presbyopia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Presbyopia (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Presbyopia (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Presbyopia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 7, 4, 4 and 7 respectively.

Presbyopia (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Presbyopia (Ophthalmology).

The pipeline guide reviews pipeline therapeutics for Presbyopia (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Presbyopia (Ophthalmology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Presbyopia (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and

molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Presbyopia (Ophthalmology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Presbyopia (Ophthalmology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Presbyopia (Ophthalmology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Global Markets Direct Report Coverage

Presbyopia - Overview

Presbyopia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Presbyopia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Presbyopia - Companies Involved in Therapeutics Development

AbbVie Inc

Cellix Bio Pvt Ltd

Eyenovia Inc

Glaukos Corp

KSbitugen Co Ltd

Kubota Vision Inc

Lenz Therapeutics LLC

Novartis AG

Ocuphire Pharma Inc

Orasis Pharmaceuticals Ltd

Plex Pharmaceuticals Inc

Reven Holdings Inc

Santen Pharmaceutical Co Ltd

Seinda Pharmaceutical Guangzhou Corp

Theratocular Biotek Co Ltd

Visus Therapeutics Inc

Vyluma Inc

Zhejiang Raytone Biotechnology Co Ltd

Presbyopia - Drug Profiles

(aceclidine + brimonidine) - Drug Profile

Product Description

Mechanism Of Action

(aceclidine + tropicamide) - Drug Profile

Product Description

Mechanism Of Action  
(brimonidine tartrate + carbachol) - Drug Profile  
Product Description  
Mechanism Of Action  
(diclofenac sodium + pilocarpine hydrochloride) - Drug Profile  
Product Description  
Mechanism Of Action  
(phentolamine mesylate + pilocarpine) - Drug Profile  
Product Description  
Mechanism Of Action  
aceclidine - Drug Profile  
Product Description  
Mechanism Of Action  
AGN-241622 - Drug Profile  
Product Description  
Mechanism Of Action  
CAP-1160 - Drug Profile  
Product Description  
Mechanism Of Action  
CLXOPH-561 - Drug Profile  
Product Description  
Mechanism Of Action  
GLK-302 - Drug Profile  
Product Description  
Mechanism Of Action  
Kinase Derivatives - Drug Profile  
Product Description  
Mechanism Of Action  
KSB-10201 - Drug Profile  
Product Description  
Mechanism Of Action  
KT-101 - Drug Profile  
Product Description  
Mechanism Of Action  
NVK-029 - Drug Profile  
Product Description  
Mechanism Of Action  
phentolamine mesylate - Drug Profile  
Product Description

Mechanism Of Action

pilocarpine - Drug Profile

Product Description

Mechanism Of Action

RPEC-1004A - Drug Profile

Product Description

Mechanism Of Action

RTP-003A - Drug Profile

Product Description

Mechanism Of Action

RTP-003B - Drug Profile

Product Description

Mechanism Of Action

Small Molecule for Presbyopia and Cataract - Drug Profile

Product Description

Mechanism Of Action

Small-Molecule Therapeutics - Drug Profile

Product Description

Mechanism Of Action

SY-301 - Drug Profile

Product Description

Mechanism Of Action

TOO-1005 - Drug Profile

Product Description

Mechanism Of Action

ursodiol - Drug Profile

Product Description

Mechanism Of Action

VP-1001 - Drug Profile

Product Description

Mechanism Of Action

Presbyopia - Dormant Projects

Presbyopia - Product Development Milestones

Featured News & Press Releases

Nov 02, 2022: Ocuphire announces peer-reviewed publication in BMC Ophthalmology for Nyxol and strategic partnership with American Society of Ophthalmic Administrators (ASOA)

Oct 28, 2022: Ocuphire announces poster presentations on Nyxol at the American Academy of Optometry Annual Meeting

Oct 20, 2022: Eyenovia announces positive results from VISION-2 phase 3 study of MicroLine as a potential on-demand treatment for presbyopia

Oct 03, 2022: Ocuphire announces upcoming presentations at European Forum 2022, Eyecelerator@AAO 2022 and the American Academy of Ophthalmology 2022 Annual Meeting

Jul 06, 2022: Eyenovia strategic partner Arctic Vision enrolls first patient in phase III clinical trial of ARVN003 (MicroLine) for Presbyopia in China

Jul 05, 2022: Arctic Vision enrols first subject in Phase III presbyopia trial

Apr 27, 2022: Visus Therapeutics announces new scientific data to be presented during the 2022 ARVO Annual Meeting

Apr 26, 2022: Ocuphire announces upcoming clinical presentation on Nyxol at ARVO 2022 Medical Meeting and MODLive! 2022

Apr 23, 2022: Orasis Pharmaceuticals announces phase 2b trial efficacy and safety results of novel presbyopia eye drop candidate, CSF-1, at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Apr 21, 2022: Orasis Pharmaceuticals announces positive phase 3 topline results of Novel Eye Drop Candidate, CSF-1, for the treatment of presbyopia

Apr 12, 2022: Orasis Pharmaceuticals to present new data on novel presbyopia candidate at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Mar 22, 2022: Visus Therapeutics initiates phase 3 pivotal trials of BRIMOCHOL PF for the treatment of presbyopia

Mar 15, 2022: Orasis Pharmaceuticals concludes phase 3 clinical trials for presbyopia candidate

Feb 08, 2022: Ocuphire completes enrollment in MIRA-3 Pivotal phase 3 clinical trial for Nyxol in RM and announces upcoming medical conference presentation

Jan 11, 2022: Glaukos announces first patient enrolled in phase 2 clinical trial for presbyopia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Presbyopia, 2022  
Number of Products under Development by Companies, 2022  
Products under Development by Companies, 2022  
Products under Development by Companies, 2022 (Contd..1)  
Number of Products by Stage and Target, 2022  
Number of Products by Stage and Mechanism of Action, 2022  
Number of Products by Stage and Route of Administration, 2022  
Number of Products by Stage and Molecule Type, 2022  
Presbyopia - Pipeline by AbbVie Inc, 2022  
Presbyopia - Pipeline by Cellix Bio Pvt Ltd, 2022  
Presbyopia - Pipeline by Eyenovia Inc, 2022  
Presbyopia - Pipeline by Glaukos Corp, 2022  
Presbyopia - Pipeline by KSbitugen Co Ltd, 2022  
Presbyopia - Pipeline by Kubota Vision Inc, 2022  
Presbyopia - Pipeline by Lenz Therapeutics LLC, 2022  
Presbyopia - Pipeline by Novartis AG, 2022  
Presbyopia - Pipeline by Ocuphire Pharma Inc, 2022  
Presbyopia - Pipeline by Orasis Pharmaceuticals Ltd, 2022  
Presbyopia - Pipeline by Plex Pharmaceuticals Inc, 2022  
Presbyopia - Pipeline by Reven Holdings Inc, 2022  
Presbyopia - Pipeline by Santen Pharmaceutical Co Ltd, 2022  
Presbyopia - Pipeline by Seinda Pharmaceutical Guangzhou Corp, 2022  
Presbyopia - Pipeline by Theratocular Biotek Co Ltd, 2022  
Presbyopia - Pipeline by Visus Therapeutics Inc, 2022  
Presbyopia - Pipeline by Vyluma Inc, 2022  
Presbyopia - Pipeline by Zhejiang Raytone Biotechnology Co Ltd, 2022  
Presbyopia - Dormant Projects, 2022



## List Of Figures

### LIST OF FIGURES

- Number of Products under Development for Presbyopia, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022

## I would like to order

Product name: Presbyopia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/P734F8047369EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P734F8047369EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

